<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470</article-id><article-id pub-id-type="doi">10.17816/ACEN.1470</article-id><article-id pub-id-type="edn">KDXZFC</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Ischemic stroke in young patients with obesity: the role of chronic non-specific inflammation</article-title><trans-title-group xml:lang="ru"><trans-title>Ишемический инсульт у молодых пациентов с ожирением: роль хронического неспецифического воспаления</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5141-3292</contrib-id><name-alternatives><name xml:lang="en"><surname>Ponomareva</surname><given-names>Maria S.</given-names></name><name xml:lang="ru"><surname>Пономарева</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>neurologist, Neurology and Neurosurgery Center, laboratory assistant, Neurology department</p></bio><bio xml:lang="ru"><p>врач-невролог Центра неврологии и нейрохирургии, ассистент каф. неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6951-2205</contrib-id><name-alternatives><name xml:lang="en"><surname>Shchepankevich</surname><given-names>Larisa A.</given-names></name><name xml:lang="ru"><surname>Щепанкевич</surname><given-names>Лариса Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Head, Neurology department, Chief, Neurology and Neurosurgery Center, curator, Neurology department</p></bio><bio xml:lang="ru"><p>д-р мед. наук, зав. Центром неврологии и нейрохирургии, куратор неврологического отделения, зав. каф. неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4579-425X</contrib-id><name-alternatives><name xml:lang="en"><surname>Pinkhasov</surname><given-names>Boris B.</given-names></name><name xml:lang="ru"><surname>Пинхасов</surname><given-names>Борис Борисович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Head, Pathophysiology department</p></bio><bio xml:lang="ru"><p>д-р мед. наук, зав. каф. патологической физиологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5883-8119</contrib-id><name-alternatives><name xml:lang="en"><surname>Tanashyan</surname><given-names>Мarine M.</given-names></name><name xml:lang="ru"><surname>Танашян</surname><given-names>Маринэ Мовсесовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Full Member of RAS, Deputy Director for research, Head, 1<sup>st</sup> Neurological department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, академик РАН, зам. директора по научной работе, рук. 1-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2373-2231</contrib-id><name-alternatives><name xml:lang="en"><surname>Antonova</surname><given-names>Ksenia V.</given-names></name><name xml:lang="ru"><surname>Антонова</surname><given-names>Ксения Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), leading researcher, 1<sup>st</sup> Neurological department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, в. н. с. 1-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6538-6069</contrib-id><name-alternatives><name xml:lang="en"><surname>Taneeva</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Танеева</surname><given-names>Елена Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Head, Stroke unit No. 2</p></bio><bio xml:lang="ru"><p>зав. региональным сосудистым центром № 2</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Novosibirsk State Medical University</institution></aff><aff><institution xml:lang="ru">Новосибирский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">State Novosibirsk Regional Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Государственная Новосибирская областная клиническая больница</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian Center of Neurology and Neurosciences</institution></aff><aff><institution xml:lang="ru">Российский центр неврологии и нейронаук</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-07" publication-format="electronic"><day>07</day><month>04</month><year>2026</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>39</fpage><lpage>47</lpage><history><date date-type="received" iso-8601-date="2026-01-12"><day>12</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-16"><day>16</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Ponomareva M.S., Shchepankevich L.A., Pinkhasov B.B., Tanashyan М.M., Antonova K.V., Taneeva E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Пономарева М.С., Щепанкевич Л.А., Пинхасов Б.Б., Танашян М.М., Антонова К.В., Танеева Е.В.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Ponomareva M.S., Shchepankevich L.A., Pinkhasov B.B., Tanashyan М.M., Antonova K.V., Taneeva E.V.</copyright-holder><copyright-holder xml:lang="ru">Пономарева М.С., Щепанкевич Л.А., Пинхасов Б.Б., Танашян М.М., Антонова К.В., Танеева Е.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/1470">https://annaly-nevrologii.com/pathID/article/view/1470</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Ischemic stroke (IS) in young adults remains an unresolved major medical, social, and demographic issue. In a quarter of cases of acute cerebrovascular events in young age their origin remains unknown (i.e., cryptogenic stroke). Obesity and its associated conditions are considered risk factors contributing to premature cerebro-metabolic disorders. Chronic non-specific inflammation (metabolic inflammation) is regarded as a potential key mechanism for vascular events in obesity, though its role in IS among obese individuals is not fully understood. Studying cytokine levels as primary markers of meta-inflammation will help assess its role in IS in young adults.</p> <p>The study <bold>aimed</bold> at evaluating the role of inflammatory mediators, biochemical and hemostatic statuses in young patients with IS of unknown etiology and obesity.</p> <p><bold>Materials and methods.</bold> A prospective study included 66 patients aged 18–50 years with IS of unknown etiology, divided into two groups: subjects with obesity (body mass index (BMI) ≥30 kg/m<sup>2</sup>; n = 34) and subjects with normal BMI (18.5–24.9 kg/m<sup>2</sup>; n = 32). Anthropometric, blood chemistry (lipid profile — low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, glucose, C-reactive protein, uric acid, homocysteine), hemostatic (factors VIII, IX, von Willebrand factor (vWF), antithrombin III, protein C), and immune (tumor necrosis factor-α (TNF-α), interleukins-6, -8, -10) blood parameters were analyzed.</p> <p><bold>Results.</bold> Significant differences were observed in key markers of chronic nonspecific inflammation among obese patients. Homocysteine levels (p = 0.0001), factors VIII (p = 0.024), IX (p = 0.003) and vWF (p &lt; 0.0001), antithrombin III (p = 0.0041), LDL cholesterol (p = 0.0382), HDL cholesterol (p = 0.0112), and uric acid (p = 0.0011) were significantly higher in obese patients. Sex stratification revealed that obesity significantly influenced triglyceride levels (p = 0.021 in men), LDL cholesterol (p = 0.0177 in men), HDL cholesterol (p = 0.0348 in men), uric acid (p = 0.0348 in men and p = 0.0229 in women), homocysteine (p = 0.0013 in women), vWF (p &lt; 0.0001 in both sexes), factor VIII (p = 0.0091 in men), factor IX (p = 0.0209 in women), and antithrombin III (p = 0.0048 in men). Similar changes were detected in inflammatory markers and proinflammatory cytokines (C-reactive protein, neutrophils, tumor necrosis factor-α, interleukin-8, -10) compared to patients with normal BMI.</p> <p><bold>Conclusion.</bold> Adipose tissue-initiated chronic nonspecific inflammation plays a significant role in the IS of unknown etiology in young adults by initiating and exacerbating endothelial dysfunction, prothrombotic, and atherosclerotic changes.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Ишемический инсульт (ИИ) у молодых людей остаётся нерешённой важной медико-социальной и демографической проблемой. В четверти случаев острых нарушений мозгового кровообращения молодого возраста этиология остаётся неуточнённой. Ожирение и сопутствующие ему патологические состояния рассматриваются как факторы риска, способствующие преждевременному развитию цереброметаболических нарушений. Как один из возможных ключевых механизмов реализации сосудистых событий при ожирении рассматривают хроническое неспецифическое воспаление (метаболическое воспаление), однако его роль в развитии ИИ у лиц с ожирением не до конца ясна. Изучение уровня цитокинов как основных маркеров метавоспаления позволит оценить роль последнего в развитии ИИ у лиц молодого возраста.</p> <p><bold>Цель </bold>исследования — оценить роль медиаторов воспаления, биохимического и гемостазиологического статусов у молодых пациентов с ИИ неуточнённой этиологии (НЭ) и ожирением.</p> <p><bold>Материалы и методы.</bold> В проспективное исследование были включены 66 пациентов 18–50 лет с ИИ НЭ, разделённые на две группы: с ожирением (индекс массы тела (ИМТ) ≥ 30 кг/м<sup>2</sup>; n = 34) и с нормальным ИМТ (18,5–24,9 кг/м<sup>2</sup>; n = 32). Анализировали антропометрические, биохимические (липидный профиль — холестерин (ХС) липопротеидов низкой (ЛПНП) и высокой (ЛПВП) плотности, глюкоза, С-реактивный белок, мочевая кислота, гомоцистеин), гемостазиологические (факторы VIII, IX, фон Виллебранда (vWF), антитромбин III, протеин С) и иммунные показатели крови (фактор некроза опухолей-α, интерлейкины-6, -8, -10).</p> <p><bold>Результаты.</bold> У пациентов с ожирением отмечены значимые различия по ряду ключевых маркеров хронического неспецифического воспаления. Уровни гомоцистеина (p = 0,0001), факторов VIII (p = 0,024), IX (p = 0,003) и vWF (p &lt; 0,0001), антитромбина III (p = 0,0041), ХС ЛПНП (p = 0,0382), ХС ЛПВП (p = 0,0112), мочевой кислоты (р = 0,0011) были значимо выше у пациентов с ожирением. Стратификация по полу показала, что ожирение значимо влияет на уровень триглицеридов (p = 0,021 у мужчин), ХС ЛПНП (p = 0,0177 у мужчин), ХС ЛПВП (p = 0,0348 у мужчин), мочевой кислоты (p = 0,0348 у мужчин и p = 0,0229 у женщин), гомоцистеина (p = 0,0013 у женщин), vWF (p &lt; 0,0001 у обоих полов), факторов VIII (p = 0,0091 у мужчин), IX (p = 0,0209 у женщин) и антитромбина III (p = 0,0048 у мужчин). Аналогичные изменения обнаружены в отношении результатов исследования маркеров воспаления и провоспалительных цитокинов (С-реактивный белок, содержание нейтрофилов, фактора некроза опухолей-α, интерлейкина-8, -10) по сравнению с пациентами с нормальным ИМТ.</p> <p><bold>Заключение.</bold> Инициируемое жировой тканью хроническое неспецифическое воспаление играет важную роль в развитии ИИ НЭ у лиц молодого возраста, инициируя и усугубляя процессы эндотелиальной дисфункции, протромботические и атеросклеротические изменения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cryptogenic stroke</kwd><kwd>obesity</kwd><kwd>inflammation</kwd><kwd>endothelial dysfunction</kwd><kwd>cytokines</kwd><kwd>young adulthood</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>криптогенный инсульт</kwd><kwd>ожирение</kwd><kwd>воспаление</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>цитокины</kwd><kwd>молодой возраст</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Schneider TR, Dittrich TD, Kahles Т., et al. First ischemic stroke in young adults: sex and age-related differences in stroke rates, risk factors, and etiologies. Eur Stroke J. 2025;10(3):882–891. doi: 10.1177/23969873251317347</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Christopher AS, John WC. The clinical approach to stroke in young adults. Stroke. 2021;3. doi: 10.36255/exonpublications.stroke.adultstroke.2021</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Potter TBH, Tannous J, Vahidy FS. A contemporary review of epidemiology, risk factors, etiology, and outcomes of premature stroke. Curr Atheroscler Rep. 2022;24(12):939–948. doi: 10.1007/s11883-022-01067-x</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ekker MS, Verhoeven JI, Schellekens MM, et al. Risk factors and causes of ischemic stroke in 1322 young adults. Stroke. 2023;54(2):439–447. doi: 10.1161/STROKEAHA.122.040524</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ohya Y, Matsuo R, Sato N, et al. Investigators for Fukuoka stroke registry. Causes of ischemic stroke in young adults versus non-young adults: a multicenter hospital-based observational study. PLoS One. 2022;17(7):e0268481. doi: 10.1371/journal.pone.0268481</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jacob MA, Ekker MS, Allach Y, et al. Global differences in risk factors, etiology, and outcome of ischemic stroke in young adults — a worldwide meta-analysis: the GOAL Initiative. Neurology. 2022;98(6):e573–e588. doi: 10.1212/WNL.0000000000013195</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Малютина Е.С., Масная М.В., Исманова В.Д. и др. Взаимосвязь фенотипов преждевременного старения с компонентами метаболического синдрома. Современные проблемы здравоохранения и медицинской статистики. 2021;(2):108–118. / Malyutina ES, Masnaya MV, Ismanova VD, et al. The relationship of the phenotypes of premature aging with the components of the metabolic syndrome. Current problems of health care and medical statistics. 2021;(2):108–118. doi: 10.24412/2312-2935-2021-2-108-118</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Антонова К.В., Танашян М.М., Раскуражев А.А. и др. Ожирение и нервная система. Ожирение и метаболизм. 2024;21(1):68–78. / Antonova KV, Tanashyan MM, Raskurazhev AA, et al. Obesity and the nervous system. Obesity and metabolism. 2024;21(1):68–78. doi: 10.14341/omet13019</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Танашян М.М., Антонова К.В. Цереброметаболическое здоровье. Анналы клинической и экспериментальной неврологии. 2025;19(2): 62–73. / Tanashyan ММ, Antonova AV. Cerebrometabolic health. Annals of Clinical and Experimental Neurology. 2025;19(2):62–73. doi: 10.17816/ACEN.1359</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Танашян М.М., Антонова К.В. Цереброметаболическое здоровье. В кн.: Аметов А.С. и др. Управление метаболическим здоровьем. М., 2025;II:117–149. / Tanashyan MM, Antonova KV. Сerebrometabolic health. In: Ametov AS, et al. Metabolic Health Management. Moscow, 2025;II:117–149. (In Russ.)</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022;29(17):2218–2237. doi: 10.1093/eurjpc/zwac187</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Virchow R. Cellular pathology as based upon physiological and pathological histology. Lecture XVI — Atheromatous affection of arteries. 1858. Nutr Rev. 1989;47(1):23–25. doi: 10.1111/j.1753-4887.1989.tb02747.x</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>González S, Schiavone M, Piñero F, et al. Obesity, metabolic abnormalities and low-grade inflammation: differential associations with subclinical atherosclerosis. Front Cardiovasc Med. 2025;12:1607399. doi: 10.3389/fcvm.2025.1607399</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pacinella G, Ciaccio AM, Tuttolomondo A. Molecular links and clinical effects of inflammation and metabolic background on ischemic stroke: an update review. J Clin Med. 2024;13(24):7515. doi:10.3390/jcm13247515</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Шишкин А.Н., Князева А.И. Эндотелиальная дисфункция у больных с ожирением. Регионарное кровообращение и микроциркуляция. 2022;21(3):4–11. / Shishkin AN, Kniazeva AI. Endothelial dysfunction in patients with obesity. Regional blood circulation and microcirculation. 2022;21(3):4–11. doi: 10.24884/1682-6655-2022-21-3-4-11</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Янковская С.В., Новикова Е.Г., Епанчинцева Е.А. и др. Ассоциация коморбидной соматической патологии с индексом массы тела и типами распределения жира у мужчин. Сибирский научный медицинский журнал. 2020;40(4):70–77. / Iankovskaia SV, Novikova EG, Epanchintseva EA, et al. Association of comorbid somatic pathology with fat distribution type and body mass index in men. Siberian Scientific Medical Journal. 2020;40(4):70–77. doi: 10.15372/SSMJ20200410</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Liu Q, Shi R, Gu Y, et al. The role of immune cell phenotypes and metabolites in the risk of ischemic stroke: a Mendelian randomization-based mediation analysis. BMC Neurol. 2025;25(1):196. doi: 10.1186/s12883-025-04205-5</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kang X, Jiao T, Wang H, et al. Mendelian randomization study on the causal effects of tumor necrosis factor inhibition on coronary artery disease and ischemic stroke among the general population. EBioMedicine. 2022;76:103824. doi: 10.1016/j.ebiom.2022.103824</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Sun W, Wang S, Nan S. The prognostic determinant of interleukin-10 in patients with acute ischemic stroke: an analysis from the perspective of disease management. Dis Markers. 2021;2021:6423244. doi: 10.1155/2021/6423244</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Su JH, Luo MY, Liang N, et al. Interleukin-6: a novel target for cardio-cerebrovascular diseases. Front Pharmacol. 2021;12:745061. doi: 10.3389/fphar.2021.745061</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Babić A, Bonifačić D, Komen V, et al. Blood biomarkers in ischemic stroke diagnostics and treatment-future perspectives. Medicina (Kaunas). 2025;61(3):514. doi: 10.3390/medicina61030514</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Пономарева М.С., Щепанкевич Л.А., Рерих К.В. и др. Метаболические предикторы течения ишемического инсульта у молодых. Анналы клинической и экспериментальной неврологии. 2025;19(1):21–29. / Ponomareva MS, Shchepankevich LA, Rerikh KV, et al. Metabolic predictors of ischemic stroke in young adults. Annals of Clinical and Experimental Neurology. 2025;19(1):21–29. doi: 10.17816/ACEN.1274</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>George MG. Risk factors for ischemic stroke in younger adults: a focused update. Stroke. 2020;51(3):729–735. doi: 10.1161/STROKEAHA.119.024156</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jaakonmäki N, Zedde M, Sarkanen T, et al. Obesity and the risk of cryptogenic ischemic stroke in young adults. J Stroke Cerebrovasc Dis. 2022;31(5):106380. doi: 10.1016/j.jstrokecerebrovasdis.2022.106380</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Rasing A, Hilkens NA, Leeuw FE. Young stroke: an update on epidemiology, emerging risk factors, and future research directions. Int J Stroke. 2026;21(1):6–13. doi: 10.1177/17474930251400524</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Martínez-Pérez LA, González-Sánchez GD, Martínez-Esquivias F, et al. The inflammatory response in metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2025. doi: 10.2174/0118715303385742250610120711</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–185. doi: 10.1038/nature21363</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Fest J, Ruiter TR, Groot Koerkamp B, et al. The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study. Eur J Epidemiol. 2019;34(5):463–470. doi: 10.1007/s10654-018-0472-y</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Романцова Т.И., Сыч Ю.П. Иммунометаболизм и метавоспаление при ожирении. Ожирение и метаболизм. 2019;16(4):3–17. / Romantsova TR, Sych YuP. Immunometabolism and metainflammation in obesity. Obesity and Мetabolism. 2019;16(4):3–17. doi: 10.14341/omet12218</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Soták M, Clark M, Suur BE, et al. Inflammation and resolution in obesity. Nat Rev Endocrinol. 2025;21(1):45–61. doi: 10.1038/s41574-024-01047-y</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hu R, Xie Y, Lu B, et al. Metabolic inflammatory syndrome: a novel concept of holistic integrative medicine for management of metabolic diseases. AME Medical Journal. 2018;3:51. doi: 10.21037/amj.2018.03.11</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549–1564. doi: 10.1161/CIRCRESAHA.119.315896</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. Biomolecules. 2020;10(2):291. doi: 10.3390/biom10020291</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Tirandi A, Sgura C, Carbone F, et al. Inflammatory biomarkers of ischemic stroke. Intern Emerg Med. 2023;18(3):723–732. doi: 10.1007/s11739-023-03201-2</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Zhu H, Hu S, Li Y, et al. Interleukins and ischemic stroke. Front Immunol. 2022; 13:828447. doi: 10.3389/fimmu.2022.828447</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021;106(3):306–319. doi: 10.1111/ejh.13560</mixed-citation></ref></ref-list></back></article>
